Antibacterial agent, antibacterial method and application
By extracting and preparing the polypeptides from the caidoba, especially the second polypeptide, the problem of insufficient inhibition effect on E. coli, Staphylococcus aureus and Candida albicans is solved, and effective inhibition of these microorganisms is achieved. Broad spectrum antibacterial properties were demonstrated.
Patent Information
- Application Number
- CN202411191636.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-28
- Publication Date
- 2024-12-06
AI Technical Summary
There are no related reports of antibacterial activity of the umami-flavored peptide of the umami-flavored peptide in the prior art, and there is a lack of effective antibacterial agents to inhibit E. coli, Staphylococcus aureus and Candida albicans.
Five polypeptides extracted and prepared from caidobacterium, including the first polypeptide, the second polypeptide, the third polypeptide, the fourth polypeptide and the fifth polypeptide, especially the second polypeptide for Candida albicans It has an inhibitory effect and is used to prepare antibacterial agents, combine excipients and other active ingredients to form medicines, skin care products, disinfectants, food preservatives and fresh preservatives.
These peptides have significant inhibitory effects on E. coli, Staphylococcus aureus and Candida albicans, and show good antibacterial effects, especially the fifth polypeptide EGHKGW on E. coli, the first polypeptide ELWR on Staphylococcus aureus and The dipolypeptide AHLRF has a particularly significant inhibitory effect on Candida albicans and has broad-spectrum antibacterial properties.
Smart Images

Figure CN119073492A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of preparation of antimicrobial peptides, and specifically relates to an antimicrobial agent, an antimicrobial method and an application. Background Art
[0002] The exploration of antimicrobial peptides has shown great potential in many fields. Antimicrobial peptides have broad-spectrum antimicrobial properties, low drug resistance and safety, providing innovative solutions for antimicrobial treatment in the fields of medicine, food preservation and agriculture. Antimicrobial peptides are not only effective against a variety of pathogens, but also exhibit a variety of biological activities such as anti-tumor and immunomodulation, opening up new avenues for the development of new drugs. With the advancement of biotechnology, it has become possible to efficiently screen and prepare antimicrobial peptides from natural resources, promoting their transformation from laboratory research to practical application.
[0003] Edible fungi are rich biological resources and contain a variety of peptide substances with antimicrobial activity. Through modern biotechnology, antimicrobial peptides in edible fungi can be systematically screened and identified, and their preparation process can be optimized to improve yield and purity. These antimicrobial peptides show broad application prospects in food preservation, medical treatment and agricultural disease prevention and control. With the improvement of regulatory standards and the strengthening of industrial cooperation, edible fungi antimicrobial peptides are expected to achieve large-scale industrial application, which will bring revolutionary changes to related industries. The prior art (see "Chen Rongrong, Li Wen, Wu Di, et al. Isolation and identification of umami peptides in Pleurotus eryngii enzymatic hydrolysate and analysis of their synergistic freshness enhancement effect [J]. Food Science, 2024, 45(01): 65-74.") reported that the peptides extracted from Pleurotus eryngii have a fresh-tasting effect. There is no related report in the prior art that Pleurotus eryngii umami peptides have antimicrobial activity. Summary of the invention
[0004] The purpose of the present invention is to provide an antibacterial agent, an antibacterial method and an application. The provided antibacterial peptide has an inhibitory effect on Escherichia coli, Staphylococcus aureus and Candida albicans and has a good antibacterial effect.
[0005] In order to solve the above technical problems, the following technical solutions are proposed:
[0006] The present invention provides an application of an antimicrobial peptide in the preparation of an antimicrobial product, wherein the antimicrobial peptide comprises at least one of a first polypeptide, a second polypeptide, a third polypeptide, a fourth polypeptide and a fifth polypeptide;
[0007] The amino acid sequence of the first polypeptide is shown in SEQ ID NO.1;
[0008] The amino acid sequence of the second polypeptide is shown in SEQ ID NO.2;
[0009] The amino acid sequence of the third polypeptide is shown in SEQ ID NO.3;
[0010] The amino acid sequence of the fourth polypeptide is shown in SEQ ID NO.4;
[0011] The amino acid sequence of the fifth polypeptide is shown as SEQ ID NO.5.
[0012] Preferably, when the antibacterial activity is to inhibit bacteria, the antimicrobial peptide comprises at least one of the first polypeptide, the second polypeptide, the third polypeptide, the fourth polypeptide and the fifth polypeptide;
[0013] When the antibacterial activity is fungistatic, the antimicrobial peptide comprises a second polypeptide.
[0014] Preferably, the bacteria include Escherichia coli and / or Staphylococcus aureus; and the fungus includes Candida albicans.
[0015] The present invention provides an antibacterial method, comprising the following steps:
[0016] The antimicrobial sample is mixed with the antimicrobial peptide and then cultured; the antimicrobial peptide comprises at least one of the first polypeptide, the second polypeptide, the third polypeptide, the fourth polypeptide and the fifth polypeptide;
[0017] The amino acid sequence of the first polypeptide is shown in SEQ ID NO.1;
[0018] The amino acid sequence of the second polypeptide is shown in SEQ ID NO.2;
[0019] The amino acid sequence of the third polypeptide is shown in SEQ ID NO.3;
[0020] The amino acid sequence of the fourth polypeptide is shown in SEQ ID NO.4;
[0021] The amino acid sequence of the fifth polypeptide is shown as SEQ ID NO.5.
[0022] The present invention provides an antibacterial agent for bacteria, comprising an antibacterial peptide, wherein the antibacterial peptide comprises at least one of a first polypeptide, a second polypeptide, a third polypeptide, a fourth polypeptide and a fifth polypeptide;
[0023] The amino acid sequence of the first polypeptide is shown in SEQ ID NO.1;
[0024] The amino acid sequence of the second polypeptide is shown in SEQ ID NO.2;
[0025] The amino acid sequence of the third polypeptide is shown in SEQ ID NO.3;
[0026] The amino acid sequence of the fourth polypeptide is shown in SEQ ID NO.4;
[0027] The amino acid sequence of the fifth polypeptide is shown as SEQ ID NO.5.
[0028] The present invention provides an antimicrobial agent for fungi, comprising an antimicrobial peptide, wherein the antimicrobial peptide comprises a second polypeptide;
[0029] The amino acid sequence of the second polypeptide is shown in SEQ ID NO.2.
[0030] Preferably, the antibacterial agent further comprises excipients and / or other active ingredients.
[0031] Preferably, the product type of the antibacterial agent includes at least one of medicines, skin care products, disinfectants, food preservatives and preservatives.
[0032] Technical effect of the present invention: The present invention provides an application of an antimicrobial peptide in the preparation of an antimicrobial product, wherein the antimicrobial peptide comprises at least one of a first polypeptide, a second polypeptide, a third polypeptide, a fourth polypeptide and a fifth polypeptide;
[0033] The amino acid sequence of the first polypeptide is shown in SEQ ID NO.1;
[0034] The amino acid sequence of the second polypeptide is shown in SEQ ID NO.2;
[0035] The amino acid sequence of the third polypeptide is shown in SEQ ID NO.3;
[0036] The amino acid sequence of the fourth polypeptide is shown in SEQ ID NO.4;
[0037] The amino acid sequence of the fifth polypeptide is shown as SEQ ID NO.5.
[0038] The first polypeptide, the second polypeptide, the third polypeptide, the fourth polypeptide and the fifth polypeptide provided by the invention are all prepared from Stropharia rugosa, have low MIC and MBC values and have good antibacterial effects.
[0039] The results of the examples show that the antimicrobial peptides provided by the present invention have inhibitory effects on Escherichia coli, Staphylococcus aureus and Candida albicans. BRIEF DESCRIPTION OF THE DRAWINGS
[0040] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required to be used in the embodiments are briefly introduced below.
[0041] Figure 1This is the antibacterial activity of Stropharia rugosa umami peptide against Escherichia coli, Staphylococcus aureus and Candida albicans;
[0042] Figure 2 This is the bactericidal concentration (MBC) of the Stropharia officinalis umami peptide AHLRF against Escherichia coli, Staphylococcus aureus and Candida albicans. DETAILED DESCRIPTION
[0043] The present invention provides an application of an antimicrobial peptide in the preparation of an antimicrobial product, wherein the antimicrobial peptide comprises at least one of a first polypeptide, a second polypeptide, a third polypeptide, a fourth polypeptide and a fifth polypeptide;
[0044] The amino acid sequence of the first polypeptide is shown in SEQ ID NO.1;
[0045] The amino acid sequence of the second polypeptide is shown in SEQ ID NO.2;
[0046] The amino acid sequence of the third polypeptide is shown in SEQ ID NO.3;
[0047] The amino acid sequence of the fourth polypeptide is shown in SEQ ID NO.4;
[0048] The amino acid sequence of the fifth polypeptide is shown as SEQ ID NO.5.
[0049] In the present invention, the expressions of the first polypeptide, the second polypeptide, the third polypeptide, the fourth polypeptide and the fifth polypeptide are only used to distinguish different polypeptides and have no special designated meaning. In the present invention, the first polypeptide, the second polypeptide, the third polypeptide, the fourth polypeptide and the fifth polypeptide are preferably prepared using Pleurotus eryngii as raw materials, and can also be artificially synthesized according to the amino acid sequence of the polypeptide; the method of preparing using Pleurotus eryngii as raw materials can be found in the prior art (see "Chen Rongrong, Li Wen, Wu Di, Zhang Zhong, Bao Dapeng, Chen Wanchao, Zhang Jinsong, Yang Yan. Isolation and identification of umami peptides in Pleurotus eryngii enzymatic hydrolysate and analysis of their synergistic freshness-enhancing effects [J]. Food Science, 2024, 45(01): 65-74."); the prior art has also reported that the first polypeptide, the second polypeptide, the third polypeptide, the fourth polypeptide and the fifth polypeptide are umami peptides and have a freshness-enhancing effect.
[0050] In the present invention, when the antibacterial activity is to inhibit bacteria, the antimicrobial peptide preferably includes at least one of the first polypeptide, the second polypeptide, the third polypeptide, the fourth polypeptide and the fifth polypeptide;
[0051] The amino acid sequence of the first polypeptide is shown in SEQ ID NO.1;
[0052] The amino acid sequence of the second polypeptide is shown in SEQ ID NO.2;
[0053] The amino acid sequence of the third polypeptide is shown in SEQ ID NO.3;
[0054] The amino acid sequence of the fourth polypeptide is shown in SEQ ID NO.4;
[0055] The amino acid sequence of the fifth polypeptide is shown in SEQ ID NO. 5. The five polypeptides of the present invention can inhibit bacteria such as Escherichia coli and / or Staphylococcus aureus.
[0056] When the antibacterial activity is fungal inhibition, the antibacterial peptide comprises a second polypeptide; the amino acid sequence of the second polypeptide is shown in SEQ ID NO. 2. The second polypeptide of the present invention can also inhibit fungi such as Candida albicans.
[0057] In an embodiment of the present invention, the bacteria include Escherichia coli and / or Staphylococcus aureus (S.aureus), more preferably Escherichia coli and / or Staphylococcus aureus; the fungus includes Candida albicans. The present invention does not specifically limit the sources of the Escherichia coli, Staphylococcus aureus and Candida albicans, and conventional strains can be used. In an embodiment of the present invention, the Escherichia coli is preferably Escherichia coli ATCC25922; the Staphylococcus aureus is preferably Staphylococcus aureus ATCC29213; the Candida albicans is preferably Candida albicans ATCC10231.
[0058] The first polypeptide, the second polypeptide, the third polypeptide, the fourth polypeptide and the fifth polypeptide of the present invention all have an inhibitory effect on Escherichia coli and Staphylococcus aureus. After the first polypeptide, the second polypeptide, the third polypeptide, the fourth polypeptide and the fifth polypeptide of the present invention are mixed, they still have an inhibitory effect on Escherichia coli and Staphylococcus aureus.
[0059] The present invention provides an antibacterial method, comprising the following steps:
[0060] The antimicrobial sample is mixed with the antimicrobial peptide and then cultured; the antimicrobial peptide comprises at least one of the first polypeptide, the second polypeptide, the third polypeptide, the fourth polypeptide and the fifth polypeptide;
[0061] The amino acid sequence of the first polypeptide is shown in SEQ ID NO.1;
[0062] The amino acid sequence of the second polypeptide is shown in SEQ ID NO.2;
[0063] The amino acid sequence of the third polypeptide is shown in SEQ ID NO.3;
[0064] The amino acid sequence of the fourth polypeptide is shown in SEQ ID NO.4;
[0065] The amino acid sequence of the fifth polypeptide is shown as SEQ ID NO.5.
[0066] The present invention does not specifically limit the mixing method, and conventional methods may be used. The culture temperature of the present invention is preferably 28-37°C, more preferably 30°C; the culture time is preferably 40-50h, more preferably 48h. The antimicrobial peptide of the present invention can inhibit bacteria such as Escherichia coli and / or Staphylococcus aureus, preferably including Escherichia coli and / or Staphylococcus aureus, more preferably Escherichia coli and Staphylococcus aureus. The technical features of the Escherichia coli and Staphylococcus aureus have been discussed above and will not be repeated here. When the antimicrobial peptide is used to inhibit fungi, the fungi preferably include Candida albicans.
[0067] The present invention provides an antibacterial agent for bacteria, including an antibacterial peptide, wherein the antibacterial peptide includes at least one of a first polypeptide, a second polypeptide, a third polypeptide, a fourth polypeptide, and a fifth polypeptide; more preferably, the antibacterial peptide includes at least one of a first polypeptide, a second polypeptide, a third polypeptide, a fourth polypeptide, and a fifth polypeptide, excipients, and other effective ingredients. The present invention can use ingredients that inhibit bacteria as other effective ingredients; the first polypeptide, the second polypeptide, the third polypeptide, the fourth polypeptide, and the fifth polypeptide of the present invention can be used alone, in combination, or in combination with other effective ingredients that have an inhibitory effect on bacteria.
[0068] The amino acid sequence of the first polypeptide of the present invention is shown in SEQ ID NO.1; the amino acid sequence of the second polypeptide is shown in SEQ ID NO.2; the amino acid sequence of the third polypeptide is shown in SEQ ID NO.3; the amino acid sequence of the fourth polypeptide is shown in SEQ ID NO.4; and the amino acid sequence of the fifth polypeptide is shown in SEQ ID NO.5. The technical features of the bacteria have been discussed above and will not be repeated here.
[0069] The present invention provides an antimicrobial agent for fungi, including an antimicrobial peptide, wherein the antimicrobial peptide includes a second polypeptide; more preferably, the second polypeptide, an excipient, and other effective ingredients. The present invention can use ingredients that inhibit fungi as other effective ingredients; the second polypeptide of the present invention can be used alone or in combination with other effective ingredients that have an inhibitory effect on fungi. The technical features of the fungi of the present invention have been discussed above and will not be repeated here.
[0070] The product type of the antibacterial agent of the present invention preferably includes at least one of medicine, skin care product, disinfectant, food preservative and preservative. In the present invention, the dosage form of the antibacterial agent preferably includes a spread and / or a spray.
[0071] In order to further illustrate the present invention, the technical solution provided by the present invention is described in detail below in conjunction with the accompanying drawings and embodiments, but they should not be construed as limiting the protection scope of the present invention.
[0072] 1. Five kinds of umami peptides from Stropharia rugosa
[0073] (1) the three-letter amino acid sequence of the first polypeptide is Glu-Leu-Trp-Arg, and the single-letter amino acid sequence is shown in SEQ ID NO. 1: ELWR;
[0074] (2) the three-letter amino acid sequence of the second polypeptide is Ala-His-Leu-Arg-Phe, and the single-letter amino acid sequence is shown in SEQ ID NO. 2: AHLRF;
[0075] (3) the three-letter amino acid sequence of the third polypeptide is Lys-Pro-Asp-Asn-Arg, and the single-letter amino acid sequence is shown in SEQ ID NO. 3: KPDNR;
[0076] (4) the three-letter amino acid sequence of the fourth polypeptide is Leu-Ala-Glu-Trp-Arg, and the single-letter amino acid sequence is shown in SEQ ID NO. 4: LAEWR;
[0077] (5) The three-letter amino acid sequence of the fifth polypeptide is Glu-Gly-His-Lys-Gly-Trp, and the single-letter amino acid sequence is shown in SEQ ID NO. 5: EGHKGW.
[0078] 2. Culture medium composition
[0079] Nutrient broth (NB) liquid medium consisted of: peptone 10 g / L, beef extract powder 3 g / L, and sodium chloride 5 g / L, with a pH of 7.2 ± 0.2;
[0080] Nutrient broth (NB) solid medium consisted of: peptone 10 g / L, beef extract powder 3 g / L, sodium chloride 5 g / L, and agar 20 g / L, with a pH of 7.2 ± 0.2;
[0081] The composition of yeast extract and malt extract (YM) agar medium is: 2 g yeast extract, 10 g malt extract, 4 g glucose, 12 g agar and 1000 mL distilled water;
[0082] The composition of the yeast extract and malt extract (YM) liquid culture medium is: 2 g of yeast extract, 10 g of malt extract, 4 g of glucose and 1000 mL of distilled water.
[0083] The above five kinds of Stropharia rugosa umami peptides and culture medium were used in the following examples.
[0084] Example 1 Antimicrobial peptide inhibition zone experiment
[0085] (1) NB solid medium and YM agar medium were prepared according to the above formula. After the two culture media were sterilized by high pressure, NB solid medium plates and YM medium plates were prepared respectively.
[0086] Escherichia coli and Staphylococcus aureus were streaked onto NB medium plates, and Candida albicans were inoculated onto YM medium plates, and cultured at 30°C overnight until obvious bacterial plaques were visible.
[0087] (2) Pick an appropriate amount of mature single colonies of Escherichia coli and Staphylococcus aureus (i.e., plaques) and inoculate them into 3 mL of NB liquid culture medium and culture at 37°C for 8 h to obtain culture medium; the culture medium is adjusted to OD 600 is 0.6.
[0088] 1) Escherichia coli
[0089] E. coli treatment group: The first to fifth polypeptides were prepared into solutions and placed on NB solid culture medium plates. One polypeptide solution was placed on each culture medium plate. Four parallel experiments were set for each polypeptide solution. The specific experiment for each polypeptide solution was as follows: 100 μL OD 600 The Escherichia coli culture fluid with a value of 0.6 is spread on the NB solid culture medium plate; after the bacterial culture medium solidifies, 4 Oxford cups with a diameter of 0.6 cm are placed on the culture medium, and 100 μL of a polypeptide solution with a concentration of 100 μL / mL is added to the 4 Oxford cups respectively, and then the culture medium plate is cultured at 30°C for 48 hours.
[0090] Positive control and negative control groups: The specific experimental process is: aspirate 100 μL OD 600 The E. coli culture solution with a value of 0.6 was spread on the NB solid culture medium plate; after the bacterial culture medium solidified, 4 Oxford cups with a diameter of 0.6 cm were placed on the culture medium. Two of the Oxford cups were used as positive controls, and 100 μL of 3 mg / mL levofloxacin hydrochloride solution was placed in each Oxford cup; the other two Oxford cups did not contain clotrimazole solution as negative controls. The culture medium plate was then cultured at 30°C for 48 hours.
[0091] 2) Staphylococcus aureus
[0092] Staphylococcus aureus treatment group: The first to fifth polypeptides were prepared into solutions and placed on NB solid culture medium plates. One polypeptide solution was placed on each culture medium plate. Three parallel experiments were set for each polypeptide solution. Specifically, 100 μL OD 600The Staphylococcus aureus culture fluid with a value of 0.6 is spread on the NB solid culture medium plate; after the bacterial culture medium solidifies, three Oxford cups with a diameter of 0.6 cm are placed on the culture medium, and 100 μL of a polypeptide solution with a concentration of 100 μL / mL is added to the three Oxford cups respectively, and then the culture medium plate is cultured at 30°C for 48 hours.
[0093] Positive control and negative control groups: The specific experimental process is: aspirate 100 μL OD 600 The Staphylococcus aureus culture fluid with a value of 0.6 was spread on the NB solid culture medium plate; after the bacterial culture medium solidified, 4 Oxford cups with a diameter of 0.6 cm were placed on the culture medium, two of which were used as positive controls, and 100 μL of 3 mg / mL levofloxacin hydrochloride solution was added to each Oxford cup; the other two Oxford cups were used as negative controls, and no clotrimazole solution was added; the culture medium plate was then cultured at 30°C for 48 hours.
[0094] After the cultivation of Escherichia coli and Staphylococcus aureus, the sizes of the inhibition zones were recorded and analyzed using a fully automatic colony counter (manufacturer: Interscience, model: SCAN500).
[0095] (3) Pick an appropriate amount of mature Candida albicans colonies (i.e., plaques) and inoculate them into 3 mL of YM liquid medium and culture at 37°C for 6 to 8 h to obtain a culture medium; adjust the culture medium to an OD of 600 OD is 0.6. Pipette 100 μL 600 100 μL of the culture solution with a pH value of 0.6 was spread on a YM solid medium plate.
[0096] Candida albicans treatment group: The first to fifth polypeptides were prepared into solutions and placed on YM solid culture medium plates. One polypeptide solution was placed on each culture medium plate. Three parallel experiments were set for each polypeptide solution. Specifically, 100 μL OD 600 The Candida albicans culture solution with a value of 0.6 was spread on a YM solid culture medium plate; after the bacterial culture medium solidified, three Oxford cups with a diameter of 0.6 cm were placed on the culture medium, and 100 μL of a polypeptide solution with a concentration of 100 μL / mL was added to the three Oxford cups respectively, and then the culture medium plate was cultured at 30°C for 48 hours.
[0097] Positive control and negative control group: Specifically: aspirate 100 μL OD 600The culture solution of Candida albicans with a value of 0.6 was spread on a YM solid culture medium plate; after the culture medium containing bacteria solidified, 4 Oxford cups with a diameter of 0.6 cm were placed on the culture medium, of which 2 Oxford cups were used as positive controls, and each Oxford cup was placed with 100 μL of clotrimazole solution, and the concentration of clotrimazole solution was 50 mg / mL; the other 2 Oxford cups were used as negative controls, and no clotrimazole solution was placed. The culture medium plate was then cultured at 30°C for 48 hours.
[0098] After the incubation, a fully automatic colony counter (manufacturer: Interscience, model: SCAN500) was used to take pictures, record and analyze the size of the inhibition zone.
[0099] The inhibitory effects of the first to fifth polypeptides on three microorganisms, Escherichia coli, Staphylococcus aureus, and Candida albicans, are shown in Tables 1 and Figure 1 As shown, it can be seen that the fifth polypeptide EGHKGW has the strongest inhibitory effect on Escherichia coli, with an inhibition zone diameter of 11.5±1.4mm; the first polypeptide ELWR has the best inhibitory effect on Staphylococcus aureus, with an inhibition zone diameter of 15.0±0.4mm; the second polypeptide AHLRF has an inhibitory effect on Candida albicans, with an inhibition zone diameter of 12.3±1.7mm, and its Escherichia coli and Staphylococcus aureus inhibition activities are second only to the fifth polypeptide EGHKGW and the first polypeptide ELWR, respectively, showing relatively good broad-spectrum antibacterial properties.
[0100] Table 1 Antibacterial activity of Stropharia rugosa umami peptides
[0101]
[0102] Note: Different letters in the same column indicate significant differences in the diameters of the inhibition zones of different peptides against the same microorganism (P<0.05), and “-” means no experiment was conducted.
[0103] Example 2 Antimicrobial peptide antibacterial concentration experiment
[0104] 1 Minimum inhibitory concentration (MIC) determination
[0105] The minimum inhibitory concentration (MIC) of Psoralea coli umami peptides against Escherichia coli, Staphylococcus aureus, and Candida albicans was determined using the two-fold dilution method. The specific steps are as follows:
[0106] Take 0.1g of the first polypeptide sample and dissolve it in 10mL of distilled water, dissolve it by ultrasonication, and dilute it in equal proportion to obtain the first polypeptide solution with concentrations of 5mg / mL, 2.5mg / mL, 1.25mg / mL, 0.63mg / mL, 0.31mg / mL, 0.16mg / mL, 0.08mg / mL, 0.04mg / mL, and 0.02mg / mL respectively. The preparation method of the second polypeptide solution to the fifth polypeptide solution is the same as that of the first polypeptide solution.
[0107] The test strains of Escherichia coli, Staphylococcus aureus, and Candida albicans were streaked on NB plates and cultured at 37°C overnight until obvious plaques were visible. An appropriate amount of mature colonies (i.e., plaques) of Escherichia coli, Staphylococcus aureus, and Candida albicans were inoculated into 3 mL of NB liquid culture medium and cultured at 37°C for 15 h. The culture medium was centrifuged to obtain the bacterial cells, which were then resuspended in physiological saline. The OD of the resuspended liquid was 600 Each NB liquid culture medium was inoculated with one bacterium to obtain Escherichia coli culture medium, Staphylococcus aureus culture medium and Candida albicans culture medium respectively.
[0108] E. coli treatment group: the E. coli resuspension was added into the deep-well plate at a ratio of 0.1% of the culture medium volume.
[0109] In the deep well plate, a total of 4 rows were added, of which 300 μL of NB liquid culture medium and 300 μL of peptide solutions of different concentrations were added to the 1st to 10th columns of the first row, and only 300 μL of NB liquid culture medium was added to the 11th to 12th columns. 0.3 μL of E. coli resuspension and 300 μL of peptide solutions of different concentrations were added to the 1st to 10th columns of the second, third and fourth rows, respectively; 300 μL of NB liquid culture medium and 0.3 μL of E. coli resuspension were added to the 11th column of the second, third and fourth rows; and only 300 μL of NB liquid culture medium was added to the 12th column of the second, third and fourth rows. The specific additions are shown in Table 2.
[0110] After all additions were completed, the deep-well plate was placed at 37°C for 24 h of shaking culture. Then the deep-well plate was removed and 200 μL was transferred to a 96-well ELISA plate to detect OD 600 Value, OD 600 The higher the value, the more turbid the bacterial solution is, which means that the microorganisms are growing and multiplying more, that is, the antibacterial effect of the antibacterial peptide is worse. The lowest drug concentration that can completely inhibit the growth of microorganisms is recorded, which is the MIC value of the drug.
[0111] Table 2 Addition of polypeptide, culture medium and culture medium
[0112]
[0113] Note: NB stands for NB liquid culture medium. The concentrations of the polypeptide solutions in the 1st to 10th columns from left to right are 10 mg / mL, 5 mg / mL, 2.5 mg / mL, 1.25 mg / mL, 0.63 mg / mL, 0.31 mg / mL, 0.16 mg / mL, 0.08 mg / mL, 0.04 mg / mL, and 0.02 mg / mL, respectively.
[0114] Staphylococcus aureus treatment group: Same as the Escherichia coli treatment group, the only difference is that 0.3 μL of Escherichia coli resuspension was replaced by 0.3 μL of Staphylococcus aureus resuspension;
[0115] Candida albicans treatment group: Same as the Escherichia coli treatment group, the only difference is that 0.3 μL of Escherichia coli resuspension was replaced by 0.3 μL of Candida albicans resuspension.
[0116] The results of the minimum inhibitory concentration of the stropharia flavor peptides against Escherichia coli, Staphylococcus aureus, and Candida albicans are shown in Table 3. It can be seen that AHLRF and EGHKGW have better inhibitory activity against Escherichia coli, and ELWR has better inhibitory activity against Staphylococcus aureus. For Candida albicans, only AHLRF has inhibitory activity against it.
[0117] It can be seen that AHLRF has good inhibitory activity against Escherichia coli, Staphylococcus aureus, and Candida albicans, with MICs of 5 mg / mL, 5 mg / mL, and 2.5 mg / mL, respectively.
[0118] Table 3 MIC of Stropharia rugosa umami peptides against Escherichia coli, Staphylococcus aureus and Candida albicans
[0119]
[0120] 2 Determination of minimum bactericidal concentration
[0121] The minimum bactericidal concentration (MBC) is the lowest drug concentration required to kill 99.9% (killing 99.9% means reducing by 3 orders of magnitude) of the test microorganisms.
[0122] Through MIC experiments, it was found that AHLRF had good inhibitory activity against Escherichia coli, Staphylococcus aureus, and Candida albicans, and its bactericidal activity was then determined as follows:
[0123] The MBC determination process of the above five kinds of Stropharia rugosa umami peptides against Escherichia coli, Staphylococcus aureus and Candida albicans is as follows: prepare NB agar medium, sterilize the NB agar medium by high pressure and cool it to 40-50°C, and prepare NB medium plates.
[0124] According to the above MIC experimental results, the bacterial solutions obtained by culturing E. coli with the AHLRF solution of 10 mg / mL, 5 mg / mL, and 2.5 mg / mL in step 1 were recorded as bacterial solutions 1 to 3;
[0125] The bacterial solutions obtained by culturing Staphylococcus aureus with AHLRF solution of 10 mg / mL, AHLRF solution of 5 mg / mL, and AHLRF solution of 2.5 mg / mL were recorded as bacterial solutions 4 to 6;
[0126] The bacterial solutions obtained by culturing Candida albicans with AHLRF solution of 10 mg / mL, AHLRF solution of 5 mg / mL, and AHLRF solution of 2.5 mg / mL were recorded as bacterial solutions 7 to 9; the above 9 bacterial solutions were subjected to MBC experiment.
[0127] The specific operation of the MBC experiment is as follows: 100 μL of the above 9 bacterial solutions are spread on NB culture medium plates, cultured at 37°C for 10 h, and photographed and counted.
[0128] The results are as follows Figure 2 As shown, it can be seen intuitively that no plaque was detected in the mixture of AHLRF solution with a concentration of 10 mg / m1 and Escherichia coli; no plaque was detected in the mixture of AHLRF solution with a concentration of 5 mg / m1 and Escherichia coli, indicating that the MBC value of AHLRF for Escherichia coli is 5 mg / mL; similarly, the MBC value of AHLRF for Staphylococcus aureus is 10 mg / mL, and the MBC value of AHLRF for Candida albicans is 5 mg / mL.
[0129] In summary, the Stropharia rugosa umami polypeptide of the present invention has antibacterial effect, and AHLRF has antibacterial effect on Escherichia coli, Staphylococcus aureus and Candida albicans.
[0130] Although the above embodiment describes the present invention in detail, it is only a part of the embodiments of the present invention, not all of the embodiments. People can also obtain other embodiments based on this embodiment without creativity, and these embodiments all fall within the protection scope of the present invention.
Claims
1. Use of an antimicrobial peptide in the preparation of an antimicrobial product, wherein the antimicrobial peptide comprises at least one of a first polypeptide, a second polypeptide, a third polypeptide, a fourth polypeptide and a fifth polypeptide; The amino acid sequence of the first polypeptide is shown in SEQ ID NO.1; The amino acid sequence of the second polypeptide is shown in SEQ ID NO.2; The amino acid sequence of the third polypeptide is shown in SEQ ID NO.3; The amino acid sequence of the fourth polypeptide is shown in SEQ ID NO.4; The amino acid sequence of the fifth polypeptide is shown as SEQ ID NO.
5.
2. The use according to claim 1, It is characterized in that When the antibacterial agent is to inhibit bacteria, the antimicrobial peptide comprises at least one of a first polypeptide, a second polypeptide, a third polypeptide, a fourth polypeptide and a fifth polypeptide; When the antibacterial activity is fungistatic, the antimicrobial peptide comprises a second polypeptide.
3. The use according to claim 2, It is characterized in that The bacteria include Escherichia coli and / or Staphylococcus aureus; the fungi include Candida albicans.
4. An antibacterial method, It is characterized in that The following steps are involved: The antibacterial sample is mixed with the antimicrobial peptide and then cultured; the antimicrobial peptide comprises at least one of the first polypeptide, the second polypeptide, the third polypeptide, the fourth polypeptide and the fifth polypeptide; The amino acid sequence of the first polypeptide is shown in SEQ ID NO.1; The amino acid sequence of the second polypeptide is shown in SEQ ID NO.2; The amino acid sequence of the third polypeptide is shown in SEQ ID NO.3; The amino acid sequence of the fourth polypeptide is shown in SEQ ID NO.4; The amino acid sequence of the fifth polypeptide is shown as SEQ ID NO.
5.
5. An antimicrobial agent for bacteria, It is characterized in that comprising an antimicrobial peptide, wherein the antimicrobial peptide comprises at least one of a first polypeptide, a second polypeptide, a third polypeptide, a fourth polypeptide and a fifth polypeptide; The amino acid sequence of the first polypeptide is shown in SEQ ID NO.1; The amino acid sequence of the second polypeptide is shown in SEQ ID NO.2; The amino acid sequence of the third polypeptide is shown in SEQ ID NO.3; The amino acid sequence of the fourth polypeptide is shown in SEQ ID NO.4; The amino acid sequence of the fifth polypeptide is shown as SEQ ID NO.
5.
6. An antifungal agent, It is characterized in that comprising an antimicrobial peptide, wherein the antimicrobial peptide comprises a second polypeptide; The amino acid sequence of the second polypeptide is shown in SEQ ID NO.
2.
7. The antibacterial agent according to claim 5 or 6, It is characterized in that The antibacterial agent also includes auxiliary materials and / or other effective ingredients.
8. The antibacterial agent according to claim 5 or 6, It is characterized in that The product types of the antibacterial agent include at least one of medicines, skin care products, disinfectants, food preservatives and antiseptics.
